264 related articles for article (PubMed ID: 31662864)
1. Risk factors and treatment of relapses in autoimmune pancreatitis: Rituximab is safe and effective.
Soliman H; Vullierme MP; Maire F; Hentic O; Ruszniewski P; Lévy P; Rebours V
United European Gastroenterol J; 2019 Oct; 7(8):1073-1083. PubMed ID: 31662864
[TBL] [Abstract][Full Text] [Related]
2. [Rituximab therapy for relapsing IgG4-autoimmune pancreatitis and cholangitis - a case report].
Mueller J; Schmidt A; Herrmann G; Caca K
Z Gastroenterol; 2015 Jan; 53(1):40-2. PubMed ID: 25594706
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune Pancreatitis: From Pathogenesis to Treatment.
Nista EC; De Lucia SS; Manilla V; Schepis T; Pellegrino A; Ojetti V; Pignataro G; Zileri Dal Verme L; Franceschi F; Gasbarrini A; Candelli M
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293522
[TBL] [Abstract][Full Text] [Related]
4. Treatment of relapsing autoimmune pancreatitis with immunomodulators and rituximab: the Mayo Clinic experience.
Hart PA; Topazian MD; Witzig TE; Clain JE; Gleeson FC; Klebig RR; Levy MJ; Pearson RK; Petersen BT; Smyrk TC; Sugumar A; Takahashi N; Vege SS; Chari ST
Gut; 2013 Nov; 62(11):1607-15. PubMed ID: 22936672
[TBL] [Abstract][Full Text] [Related]
5. Rituximab Maintenance Therapy Reduces Rate of Relapse of Pancreaticobiliary Immunoglobulin G4-related Disease.
Majumder S; Mohapatra S; Lennon RJ; Piovezani Ramos G; Postier N; Gleeson FC; Levy MJ; Pearson RK; Petersen BT; Vege SS; Chari ST; Topazian MD; Witzig TE
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1947-1953. PubMed ID: 29526692
[TBL] [Abstract][Full Text] [Related]
6. Steroid Therapy and Steroid Response in Autoimmune Pancreatitis.
Matsubayashi H; Ishiwatari H; Imai K; Kishida Y; Ito S; Hotta K; Yabuuchi Y; Yoshida M; Kakushima N; Takizawa K; Kawata N; Ono H
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905944
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Follow-Up and Immunomonitoring of Relapsing Type 1 Autoimmune Pancreatitis Treated With Rituximab.
Le Cosquer G; Ribes D; Faguer S; Jeune M; Alric L; Bournet B; Buscail L
Pancreas; 2022 May; 51(5):452-462. PubMed ID: 35835119
[TBL] [Abstract][Full Text] [Related]
8. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy.
Ghazale A; Chari ST; Zhang L; Smyrk TC; Takahashi N; Levy MJ; Topazian MD; Clain JE; Pearson RK; Petersen BT; Vege SS; Lindor K; Farnell MB
Gastroenterology; 2008 Mar; 134(3):706-15. PubMed ID: 18222442
[TBL] [Abstract][Full Text] [Related]
9. Presentation and management of post-treatment relapse in autoimmune pancreatitis/immunoglobulin G4-associated cholangitis.
Sandanayake NS; Church NI; Chapman MH; Johnson GJ; Dhar DK; Amin Z; Deheragoda MG; Novelli M; Winstanley A; Rodriguez-Justo M; Hatfield AR; Pereira SP; Webster GJ
Clin Gastroenterol Hepatol; 2009 Oct; 7(10):1089-96. PubMed ID: 19345283
[TBL] [Abstract][Full Text] [Related]
10. Autoimmune Pancreatitis and IgG4-Related Disease: The Storiform Discovery to Treatment.
Okazaki K
Dig Dis Sci; 2019 Sep; 64(9):2385-2394. PubMed ID: 31363956
[TBL] [Abstract][Full Text] [Related]
11. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients.
Miki M; Fujimori N; Oono T; Kawabe K; Ohno A; Matsumoto K; Teramatsu K; Tachibana Y; Ogawa Y
J Dig Dis; 2019 Mar; 20(3):152-158. PubMed ID: 30701685
[TBL] [Abstract][Full Text] [Related]
12. [Autoimmune pancreatitis].
Petersen B; Schaffalitzky de Muckadell OB
Ugeskr Laeger; 2019 Nov; 181(46):. PubMed ID: 31791461
[TBL] [Abstract][Full Text] [Related]
13. Predictors of disease relapse in IgG4-related disease following rituximab.
Wallace ZS; Mattoo H; Mahajan VS; Kulikova M; Lu L; Deshpande V; Choi HK; Pillai S; Stone JH
Rheumatology (Oxford); 2016 Jun; 55(6):1000-8. PubMed ID: 26888853
[TBL] [Abstract][Full Text] [Related]
14. Advances in IgG4-related pancreatobiliary diseases.
Kamisawa T; Zen Y; Nakazawa T; Okazaki K
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):575-585. PubMed ID: 30047448
[TBL] [Abstract][Full Text] [Related]
15. Treatment and outcomes in patients with IgG4-related disease using the IgG4 responder index.
Fernández-Codina A; Pinilla B; Pinal-Fernández I; López C; Fraile-Rodríguez G; Fonseca-Aizpuru E; Carballo I; Brito-Zerón P; Feijóo-Massó C; López-Dupla M; Cid MC; Martínez-Valle F; ; ;
Joint Bone Spine; 2018 Dec; 85(6):721-726. PubMed ID: 29452298
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in autoimmune pancreatitis: type 1 and type 2.
Kamisawa T; Chari ST; Lerch MM; Kim MH; Gress TM; Shimosegawa T
Gut; 2013 Sep; 62(9):1373-80. PubMed ID: 23749606
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin G4-Related Disease Responder Index Correlates With the Risk of 1-Year Relapse in Type 1 Autoimmune Pancreatitis.
Rogger TM; De Marchi G; Brozzi L; Amodio A; Orsolini G; de Pretis N; Conti Bellocchi MC; Crinò SF; Gabbrielli A; Ciccocioppo R; Frulloni L
Pancreas; 2021 Jul; 50(6):879-881. PubMed ID: 34347736
[TBL] [Abstract][Full Text] [Related]
18. The treatment outcomes in IgG4-related disease.
Karim AF; Bansie RD; Rombach SM; Paridaens D; Verdijk RM; van Hagen PM; Van Laar JAM
Neth J Med; 2018 Aug; 76(6):275-285. PubMed ID: 30152392
[TBL] [Abstract][Full Text] [Related]
19. Recent Advances in Autoimmune Pancreatitis.
Hart PA; Zen Y; Chari ST
Gastroenterology; 2015 Jul; 149(1):39-51. PubMed ID: 25770706
[TBL] [Abstract][Full Text] [Related]
20. Relapse Rate in Survivors of Acute Autoimmune Thrombotic Thrombocytopenic Purpura Treated with or without Rituximab.
Falter T; Herold S; Weyer-Elberich V; Scheiner C; Schmitt V; von Auer C; Messmer X; Wild P; Lackner KJ; Lämmle B; Scharrer I
Thromb Haemost; 2018 Oct; 118(10):1743-1751. PubMed ID: 30235478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
